RxDoctor Payments Data

Monica Brown

Family · Lebanon, OHNPI 1548596976

Payments from drug & device makers

$2,061in general payments, 2019–2025

Across 106 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$449
  • AstraZeneca$359
  • Novo Nordisk$286
  • Lilly USA, LLC$254
  • Pfizer$152
  • GSK$65
  • plus $496 from 14 others

What the payments were for

  • Food & beverage$2,061100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,061 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$27,321
Medicare patients
204
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$34,303
MounjaroTirzepatide13$15,869
EliquisApixaban16$15,228
Breo ElliptaFluticasone/Vilanterol13$5,888
SymbicortBudesonide/Formoterol Fumarate15$3,606
Albuterol Sulfate HfaAlbuterol Sulfate88$2,555
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,872
Atorvastatin Calcium159$1,181
Pantoprazole Sodium68$1,085
Duloxetine Hcl37$1,006
Celecoxib25$956
Ondansetron Hcl13$950
Levothyroxine Sodium81$875
Oxybutynin Chloride ErOxybutynin Chloride14$870
Mometasone Furoate21$693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$286$34,30319 claims
Lilly USA, LLCMounjaro$254$15,86913 claims
PfizerEliquis$152$15,22816 claims
GSKBreo Ellipta$65$5,88813 claims
AstraZenecaSymbicort$359$3,60615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.

Other family in Lebanon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →